Peramivir
Navigation Links
Peramivir in Medical News
A Single Dose of Peramivir is Effective and Well-Tolerated at Both 300
mg and 600 mg Dose Levels
BIRMINGHAM, Ala., Oct. 28 /PRNewswire-FirstCall/ -- BioCryst
Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced that a double-blind,
placebo-controlled, Phase 2 study of intravenous (i.v.) pe...
...at many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the...
BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update
... and potential emergency use of intravenous (i.v.) peramivir in the U.S. "Our efforts at BioCryst remain focused on moving our leading peramivir and forodesine clinical development programs forwa...iligently with government agencies to provide i.v. peramivir as a potential treatment option for an influenza e...BioCryst to Present at the 11th Annual BIO CEO & Investor Conference
...at many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the......at many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the...
BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
...at many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the pe...BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
...ear contract to BioCryst to advance development of peramivir to treat seasonal and life-threatening influenza. ...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that the...BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007
...r contract to BioCryst for advanced development of peramivir to treat seasonal and life-threatening influenza. ...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by i.m. injection ...be correct, that final results and analysis of the peramivir Phase II trial may differ from the preliminary res...BioCryst’s Bird Flu Drug Enjoys Fast-Track Review By FD
...n have a new form of anti-viral therapy to effectively manage the bird flu threat. "The FDA's decision supports our belief in the potential of peramivir as an effective therapy for the treatment of influenza, including highly virulent, life-threatening strains like those associated with avian influenza...Peramivir in Medical Technology
BIRMINGHAM, Ala., July 17 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX ) today announced positive results from two Phase 3 studies of intravenous (i.v.) peramivir in patients with seasonal influenza. The studies were sponsored by BioCryst's partner Shionogi & Co.,...
BIRMINGHAM, Ala., May 7 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX ) today announced that an update regarding peramivir and its first quarter 2009 financial results will be released on Friday, May 8, 2009. Following the release, BioCryst will host a conference call and Web...
BIRMINGHAM, Ala., Feb. 23 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX ) today announced that the full data set from an exploratory Phase 2 study of peramivir in patients hospitalized for influenza was presented by the study's Principal Investigator, Dr. Michael G. Ison, Assi...
BIRMINGHAM, Ala., July 28 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced preliminary results of a Phase II study of intravenous (i.v.) peramivir administered via a single dose injection in the outpatient setting for the treatment of seasonal influenza...
BIRMINGHAM, Ala., July 10 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced the initiation of a Phase II study of intramuscular (i.m.) peramivir for the treatment of seasonal influenza. The double-blind, placebo-controlled, parallel group Phase II tria...
BioCryst Says Study Confirms and Extends Evidence Seen in a Previous Study BIRMINGHAM, Ala., May 02, 2007 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. today announced that investigators at St. Jude Children's Research Hospital, Memphis, TN, reported favorable results evaluating peramiv...
...r contract to BioCryst for advanced development of peramivir to treat seasonal and life-threatening influenza. ...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by i.m. injection ...be correct, that final results and analysis of the peramivir Phase II trial may differ from the preliminary res...
BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
BIRMINGHAM, Ala., May 8 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced that, based on discussions with the U.S. Department of Health and Human Services/Biomedical Advanced Research and Development Authority (HHS-BARDA), it is preparing a portion of its i...BIRMINGHAM, Ala., May 7 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX ) today announced that an update regarding peramivir and its first quarter 2009 financial results will be released on Friday, May 8, 2009. Following the release, BioCryst will host a conference call and Web...
BIRMINGHAM, Ala., Feb. 23 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX ) today announced that the full data set from an exploratory Phase 2 study of peramivir in patients hospitalized for influenza was presented by the study's Principal Investigator, Dr. Michael G. Ison, Assi...
BIRMINGHAM, Ala., July 28 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced preliminary results of a Phase II study of intravenous (i.v.) peramivir administered via a single dose injection in the outpatient setting for the treatment of seasonal influenza...
BIRMINGHAM, Ala., July 10 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced the initiation of a Phase II study of intramuscular (i.m.) peramivir for the treatment of seasonal influenza. The double-blind, placebo-controlled, parallel group Phase II tria...
BioCryst Updates Peramivir Clinical Development Plan
BIRMINGHAM, Ala., Jan. 23 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today provided an update on activities conducted following release of the preliminary Phase II data and outlined the resulting clinical development plan for intramuscular (i.m.) peramivir. (Lo...BioCryst Says Study Confirms and Extends Evidence Seen in a Previous Study BIRMINGHAM, Ala., May 02, 2007 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. today announced that investigators at St. Jude Children's Research Hospital, Memphis, TN, reported favorable results evaluating peramiv...
BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Pharmacokinetic and Safety Profile of the Intramuscular Formulation of Peramivir Supports Further Evaluation as Treatment for Acute Influenza BIRMINGHAM, Ala., June 18, 2007 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. presented results from two Phase I clinical studies of an intramusc......r contract to BioCryst for advanced development of peramivir to treat seasonal and life-threatening influenza. ...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by i.m. injection ...be correct, that final results and analysis of the peramivir Phase II trial may differ from the preliminary res...
Peramivir in Biological News
Peramivir protects mice from lethal H5N1 infection
... The antiviral drug peramivir might offer humans significant protection during a...day versus eight days); route of administration of peramivir (intramuscular injections alone versus intramuscul...ice). In all cases, the investigators administered peramivir to mice one hour after nasally administering a let...Peramivir in Biological Technology
BIRMINGHAM, Ala., Sept. 19 /PRNewswire-FirstCall/ -- BioCryst
Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced preliminary findings
from a Phase II study with intramuscular (i.m.) injection of peramivir, the
Company's product candidate for the treatment of seasonal and
life-threatening i...
...at many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the...
...ty of five days of therapy with either 200 mg i.v. peramivir per day, 400 mg i.v. peramivir per day or 75 mg oral oseltamivir twice a day, in ...ficacy endpoints between the three treatment arms. peramivir was generally safe and well-tolerated at these dos...
...ble-Blind, Placebo-Controlled Study of Intravenous peramivir in Acute Influenza Patients" (Poster Session # 302...y and Pharmaceutical Sciences. About Peramivir peramivir is an antiviral agent that inhibits the interactio...d of influenza within a host. In laboratory tests, peramivir has shown activity against viral strains that are ...
BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update
... in clinical development costs associated with the peramivir program, a reduction in manufacturing costs associated with both the peramivir and Forodesine HCl programs and a reduction in cos...red in the Phase 3 program of intramuscular (i.m.) peramivir for outpatient influenza. The Company initiated t...BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference
...at many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the......at many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the...
BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
...0, 2007. This decrease is driven by a reduction in peramivir clinical development costs and associated revenue ... in clinical development costs associated with the peramivir program, a reduction in manufacturing costs associated with both the peramivir and forodesine HCl program and a reduction in cost......ty of five days of therapy with either 200 mg i.v. peramivir per day, 400 mg i.v. peramivir per day or 75 mg oral oseltamivir twice a day, in ...ficacy endpoints between the three treatment arms. peramivir was generally safe and well-tolerated at these dos...
BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the pe......ble-Blind, Placebo-Controlled Study of Intravenous peramivir in Acute Influenza Patients" (Poster Session # 302...y and Pharmaceutical Sciences. About Peramivir peramivir is an antiviral agent that inhibits the interactio...d of influenza within a host. In laboratory tests, peramivir has shown activity against viral strains that are ...
BioCryst to Present at the JMP Healthcare Focus Conference
...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the pe...BioCryst to Present at UBS 2008 Global Life Sciences Conference
...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the pe...Other TagsXDROther Contentshospitalhospitalhospitalhospitalhospitalhospitalhospitalhospitalpeoplepeoplepeoplepeoplepeoplepeoplepeoplepeoplepeoplehealthyhealthyhealthyhealthyhealthyhealthyhealthyhealthyhealthyhealthyheterophilepointerhiphiphiphiphiphipprocedureprocedureprocedureprocedureprocedureprocedureprocedureprocedureprocedureprocedure
(Date:11/25/2009)...swire/--TheAmericanAssociationforHomecareendorsest...hisdesignedtosubstantiallyimprovetoolsandresources...ucedbySen.GeorgeLeMieux(R-Fla.). ,, TheLeMieuxb...forHomecareoutlinedinits13-pointanti-fraudactionpl....Thoseprovisionsincludecallingforreal-timeauditsan...
(Date:11/25/2009)...d into the body on a carefully engineered, fingern...minate tumors in mammals, scientists report this w... . , The new approach, pioneered by bioengineers...stic disks impregnated with tumor-specific antigen...mmalian immune system to attack tumors. The new pa...
(Date:11/25/2009)...r in children with autism and related conditions c...medication combined with a structured training pro...earchers and their colleagues. , Published in t...ican Academy of Child and Adolescent Psychiatry , ...of Mental Health (NIMH) Research Units on Pediatri...
(Date:11/25/2009)...ed parts of speech colored perception of sounds ,... People can "hear" not only with their ears, but a...act, sensations on the skin designed to mimic cert...r sounds better, the Canadian scientists found. ,...ld use tactile information in this way," said Brya...
(Date:11/25/2009)...to include cost-effective, sustainable distance tr...essionals in developing world. , ...- Elluminate, Inc. , the leader in web, audio, v... 21st century teaching, learning, and collaboratio...ive was awarded iNACOL,s first-ever Outstanding a...
Breaking Medicine News(10 mins):Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2Health News:Implant-based cancer vaccine is first to eliminate tumors in mice 2Health News:Parent training key to improved treatment of behavior problems in children with autism 2Health News:Your Skin Can Help Your Ears Listen 2Health News:Your Skin Can Help Your Ears Listen 3Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 2Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 3Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 4Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 5[1] American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009'[1] Implant-based cancer vaccine is first to eliminate tumors in mice[0] Parent training key to improved treatment of behavior problems in children with autism[0] Your Skin Can Help Your Ears Listen [1] Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice
(Date:11/23/2009)...t a common oral bacterium may exacerbate autoimmun...Unique Lipids from a Common Human Bacterium Repres...ng Autoimmunity," appears in the December 2009 iss...tiple sclerosis (MS), a disease where the immune s...early 1 in 700 people in the United States. Patie...
(Date:11/23/2009)...highest resolution images of peptides attaching to...tanding how biomolecules manipulate the growth cry...or kidney stones using biomolecules. , The resea...f the journal Proceedings of the National Academy... mineral surfaces by accelerating, switching and i...
(Date:11/23/2009)...icrobiologist Louis Tisa has received two grants t...ctinorhizal plants, widespread woody plants with p...soils. , The United States Department of Agricu...r, cellular and biomedical sciences, $399,000 to e...eria Frankia and Casuarina, an actinorhizal plant....
Breaking Biology News(10 mins):Factors from common human bacteria may trigger multiple sclerosis 2Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 2Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 3UNH prof. receives nearly $500,000 to research environmentally significant plants 2Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference 12484 1Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference 12484 2Baylor Dallas Opens Nations First Neurosurgical OR Suite Featuring BrainSUITE iMRI GE Healthcare MR Surgical Technology 48035 1Baylor Dallas Opens Nations First Neurosurgical OR Suite Featuring BrainSUITE iMRI GE Healthcare MR Surgical Technology 48035 2Isis Pharmaceuticals to Present at Needhams 8th Annual Life Sciences Conference 48033 1| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |